VTVT - vTv Therapeutics

-

$undefined

N/A

(N/A)

vTv Therapeutics NasdaqCM:VTVT vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.

Location: 3980 Premier Drive, Suite 310, High Point, NC, 27265, United States | Website: https://vtvtherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

12.86M

Cash

31.06M

Avg Qtr Burn

-5.915M

Short % of Float

1.16%

Insider Ownership

35.60%

Institutional Own.

22.05%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Cadisegliatin (TTP399) Details
Type 1 diabetes, Diabetes

Phase 3

Update

HPP737 Details
Psoriasis, Skin disease/disorder

Phase 2

Update

Cadisegliatin (TTP399) Details
Diabetes, Type 2 diabetes

Phase 2

Initiation

TTP273 (Oral GLP-1R) Details
Diabetes, Type 2 diabetes, Cystic fibrosis

Phase 1/2

Update

TTP488 (Azeliragon) (RAGE) Details
Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder

Failed

Discontinued